

EXTRA MURAL RESEARCH

Search for Potential Anticancer Agents:

Evaluation of Anticancer Activity of Carcinosis, Apis and Thuja

Soma Samanta, A.U. De, P.K. Tarafder and Tarun Jha*

Abstract

As a part of our composite programme of rational drug discovery, homeopathic medicines *Carcinosis*, *Apis* and *Thuja* with different strengths were taken into consideration for anticancer activity to find out the effectiveness of these drugs in animal models. Here, we have reported the anticancer activity of *Carcinosis* of some strengths from a manufacturer where tumor cell count as well as tumor weight inhibition were considered as the biological activity parameters. Anticancer activity of all collected medicines of *Carcinosis*, *Apis* and *Thuja* were evaluated against another animal model considering the survival time as the biological activity parameter. Result showed that the survival time of *Carcinosis* is proportionally increased with potency and the observed result also satisfies the validity of the animal model for anticancer evaluation as well as supports our earlier observations. *Apis* and *Thuja* did not show promising result to increase the survival time.

Keywords : apis, carcinosis, thuja, ehrlich ascites carcinoma, survival time

Introduction

As a part of our composite programme of rational drug discovery¹⁻²¹, homeopathic medicines were taken into consideration as complementary medicines. Anticancer evaluation of different strength of *Carcinosis*, *Apis mel.* and *Thuja occ.* were reported previously^{4,11,21}. It was found that the anticancer activity of *Carcinosis* increased with dilution, i.e., potency of *Carcinosis* increases anticancer activity¹¹. *Carcinosis* 200 and *Carcinosis* 1M showed good anticancer activity in the animal model⁶ but *Apis mel.* and *Thuja occ.* did not show any significant anticancer activity in that animal model⁴. There was no similarity between the anticancer activity and the potency of samples of *Apis mel.* and *Thuja occ.*⁶. While working with *Carcinosis*, to quantify its potential as an anticancer agent in Ehrlich Ascites Carcinoma (EAC) cells, we observed certain discrepancies in the actual content of active constituents in the preparations available in the market and we reported those findings^{12,21}. The incomplete specifications in the Homeopathic Pharmacopoeia²² in this area encouraged us to characterize these homeopathic medicines before going for their further evaluation of biological activity. Mother tinctures of *Thuja occidentalis*, *Apis mellifica*, *Lycopodium clavatum* and *Hydratis canadensis* were

chosen for that study. It was found that because of the discrepancy in the drug contents of various marketed mother tincture preparations, it was wise to make dilutions from their accurately measured drug contents and study their anticancer potential against EAC cells and these part of the work was also reported¹².

After characterization of the mother tincture of *Thuja*, *Apis*, *Hydratis* and *Lycopodium*, specific quantity of residues of these after evaporation of solvents were evaluated for their anticancer activity against EAC cells in Swiss Albino mice⁴. Anticancer activities of orally administered *Thuja occidentalis*, *Apis mellifica*, *Lycopodium clavatum* and *Hydratis canadensis* obtained from different manufacturers like Hahnemann Publishing Co. Pvt. Ltd. (India), C Ringer & Co. (India), Dr. Willmar Schwable India Pvt. Ltd. (India), Dr. Willmar Schwable Karlsruhe (Germany) and SBL Pvt. Ltd. (India) were also reported⁴. Anticancer activities of the same administered intraperitoneally were also reported⁴. It was found that, though, the anticancer activity of *Thuja occidentalis*, *Apis mellifica*, *Lycopodium clavatum* and *Hydratis Canadensis* were very less but the oral route was more effective than the intraperitoneal one. Hence, supported the route of administration of Homeopathic drugs in complementary medicines⁴.

In traditional medicines, *Carcinosis* is a very common drug used for the treatment of cancer. Although the

*Address for correspondence : Prof. Tarun Jha, Department of Pharmaceutical Technology, P.O. Box 17020, Jadavpur University, Kolkata – 700032, India
E-mail: tjupharm@yahoo.com

anticancer activity of Carcinisin was evaluated initially^{4,6, 11, 21} but to study effects of the product (Carcinisin) of different strengths from a different manufacturer (Dr. Reckeweg & Co., Germany) were taken for the test in this part of the work based on those earlier findings to get a clear broad picture of this kind of homeopathic anticancer drug. Our aim was to search for the potential anticancer agents and here anticancer activity of potentised and dynamised Carcinisin, Thuja and Apies were evaluated against Ehrlich Ascites Carcinoma (EAC) cells in Swiss Albino Mice and were reported as a continuation of our earlier reported work^{4, 6, 11-12, 21}. In comparison to our previous study⁶ on anticancer activity of Carcinisin from a different manufacturer (Hahnemann Publishing Co. Pvt. Ltd., India), it was found that there was a similarity in anticancer activity of the same potencies of Carcinisin and biological activity increases with the potency. Result also satisfied the validity of this animal model for anticancer evaluation of homeopathic drugs.

Here, we have reported the anticancer activity of Carcinisin of different strengths from a different manufacturer than the earlier reported ones where tumor cell count as well as tumor weight inhibition were considered as the anticancer activity parameters. Attempt was also made to find out effects of homeopathic medicines on cancer in respect to the survival time of animals to validate our earlier work of homeopathic medicines on animal experimentation.

Materials and Methods

Carcinisin was obtained from Dr. Reckeweg & Co. (Germany). Apis mel and Thuja were manufactured by Hahnemann Publishing Co. Pvt. Ltd. (India).

Evaluation of anticancer agent

Carcinocin was evaluated for anticancer activity *in vivo* against Ehrlich Ascites Carcinoma (EAC) cells in Swiss Albino mice using EAC fluid (tumor) weight and EAC cell count as the biological activity parameters. Amongst various *in vivo* evaluation systems in practice, this method has been standardized and reported from our laboratory earlier^{4, 6, 9-11, 13, 16-17, 19-21}.

Survival time determination

Two groups of Swiss Albino mice, each containing 8 healthy mice of the same sex, approximately of the same age and body weight (18-20g) were selected at random and kept in two different cages under identical conditions. One of these two groups served as the control while the other as the test. EAC cells were collected from the donor mouse and were resuspended in sterile isotonic solution. The numbers of tumor cells

per ml of this suspension were counted under a microscope with the help of a haemocytometer. A definite number (about 2×10^6 cells/0.2 ml) of these living viable cells was injected or implanted into the peritoneal cavity of each mouse. In this instance, the tumor cells multiplied relatively freely within the peritoneal cavity and ascites developed. A day of incubation was allowed to establish the disease in the body before starting the drug administration. From the 2nd day of transplantation up to the 8th day, different strengths of drugs were given from a solution of two drops in 10 ml distilled water to each mouse orally (buccal cavity was soaked properly) in the test group at 24 hr interval. Thus, seven consecutive dosage of the drug were administered to each mouse in the test group. Mice were inspected daily for survival time for the period of 30 days. Animals were also inspected for the change in their body weight every alternate day over this period.

Results and Discussion

Carcinisin 6, Carcinisin 30, Carcinisin 200 and Carcinisin 1000 were evaluated for their anticancer activity *in vivo* against Ehrlich Ascites Carcinoma (EAC) cells in Swiss Albino mice using EAC fluid (tumor) weight and EAC cell count as activity parameters. In comparison between % inhibition of ascitic cells and % inhibition of ascitic fluid it was found that there was no similarity. Even in case of inhibition of ascites fluid, it was found that with the increase in the dilution, anticancer activity increased accordingly for Carcinisin 6, 30 and 200 but Carcinisin 1M does not showed the expected result which is shown in Table 1. It may be due to the nonuniformity of the actual content of active constituents in the preparation available in the market as reported by our earlier work¹¹.

We have also check effects of the homeopathic medicines Carcinocin, Apis and Thuja on cancer in respect to survival time in cancer. The results are shown in Table 2, Table 3 and Table 4 respectively.

Conclusion

In search of potential anticancer agent, anticancer evaluation was performed on different marketed homeopathic medicines. Different homeopathic medicines were collected from different companies like a homeopathic manufacturing company from West Bengal, i.e., Hahnemann Publishing Co.Pvt.Ltd., an Indian manufacturing company, i.e., C. Ringer and Co. (India), a German manufacturing company, i.e., Dr. Willmar Schwable Karlsruhe (Germany) and a US based company, i.e., BT, USA. In the anticancer evaluation of different strengths of Carcinisin of various manufacturers, it was found in our previous report¹¹ that products from some companies showed good anticancer

Table 1: Anticancer activity of Carcinisin 6, Carcinisin 30, Carcinisin 200 and Carcinisin 1M against EAC cell line in Swiss Albino mice administered orally

Samples	No. of animals in each group	No. of EAC cells inoculated	Avg. no. of ascitic cells/ml in Control (C)	Avg. no. of ascitic cells/ml in Test (T)	% Inhibition of ascitic cells (1-T/C) x100	Avg. wt of ascitic fluid in Control (C)	Avg. wt of ascitic fluid in Test (T)	% Inhibition of ascitic fluid (1-T'/C') x100
Carcinisin 6	8	2.04x 10 ⁶	50.98x10 ⁶	27.15 x 10 ⁶	46.74	0.82	0.72	11.87
Carcinisin 30	8	2.04x10 ⁶	50.98x10 ⁶	33.59 x 10 ⁶	34.11	0.82	0.67	17.99
Carcinisin 200	8	2.10x10 ⁶	41.60x10 ⁶	39.39 x 10 ⁶	5.31	1.85	1.19	35.68
Carcinisin 1000	8	2.10x10 ⁶	41.60x10 ⁶	29.19 x 10 ⁶	29.83	1.85	1.55	16.22

Table 2: Observation of survival time against Ehrlich Ascites Carcinoma cells of Carcinisin

Group	No. of animals in each group	No. of EAC cells inoculated	After 15 days No. of live animal	After 30 days No. of live animal
Control	8	2.03 x 10 ⁶	1	0
Carcinisin 6	8	2.03 x 10 ⁶	4	0
Carcinisin 200	8	2.03 x 10 ⁶	2	0
Control	8	2.02 x 10 ⁶	2	0
Carcinisin 30	8	2.02 x 10 ⁶	2	0
Carcinisin 1M	8	2.02 x 10 ⁶	6	3

Table 3: Observation of survival time against Ehrlich Ascites Carcinoma cells of Thuja

Group	No. of animals in each group	No. of EAC cells inoculated	After 15 days No. of live animal	After 30 days No. of live animal
Control	8	2.12 x 10 ⁶	2	0
Thuja 30	8	2.12 x 10 ⁶	1	0
Thuja 200	8	2.12 x 10 ⁶	2	0

Table 4: Observation of survival time against Ehrlich Ascites Carcinoma cells of Apis

Group	No. of animals in each group	No. of EAC cells inoculated	After 15 days No. of live animal	After 30 days No. of live animal
Control	8	2.05 x 10 ⁶	2	0
Apis 30	8	2.05 x 10 ⁶	3	0
Apis 200	8	2.05 x 10 ⁶	2	0

activity in the animal model where cell count and tumor weight were considered as the biological activity parameters. Anticancer activity of Carcinosis increased with dilutions, i.e., potency of Carcinosis increased anticancer activity but other products from some other companies did not showed the expected activity with dilutions, even there were discrepancies in results between these two parameters, i.e., % inhibition of cell count and the % inhibition of tumor weight of the ascitic fluid. It may be due to the nonuniformity of the actual content of active constituents in the preparations available in the market. There is incomplete specification in Homeopathic Pharmacopoea²² which encourages us to determine the % content of active constituents and we have reported previously¹² the discrepancy in the drug contents of various marketed mother tinctures of Homeopathic preparations. Thus, it is better to make dilutions from their accurately measured drug contents and evaluation of anticancer activity of these ones. Due to non-availability of the mother tincture of Carcinosis, we evaluated anticancer activity of various dilution of Carcinosis available from different manufacturers. We had also checked the effect of the homeopathic medicines Carcinosis, Apis and Thuja on cancer in respect to survival time in another animal model. It is also observed that for Carcinosis 1M, survival time was the highest. Other anticancer homeopathic medicines like Apis mel. and Thuja occ did not show any significant anticancer activity in the animal model so far survival time was considered as the biological activity parameter. There was no similarity between the anticancer activity and potency of samples of these Apis mel. and Thuja occ. This preliminary study showed the importance of animal experiments for homeopathic medicines and demands detail study in future.

Acknowledgement

Authors are thankful to Deptt. of Indian Systems of Medicine & Homoeopathy (ISM&H), Ministry of Health & Family Welfare, Govt. of India for providing financial support, under Extra-Mural Research scheme.

Reference

1. Satya Prakash Vishnoi, Anindya Basu, Sk. Mahasin Alam, Soma Samanta, Tarun Jha Evaluation of the antipyretic potential of methanol extract of the leaves of *Abies Spectabilis* (D.Don) spach, *Natur. Prod. Rad.* 6 2007: 369-371.
2. Soma Samanta, Sk. Mahasin Alam, Soumya Basu, Tapas Maji, Dilip Kumar Roy, Tarun Jha Chemotherapeutic approach to Prolonged Survival Time in Combination with Immunization and Glutamic Acid Derivatives with Antitumor Activity in Tumor-Bearing Mice, *Biol. Pharm. Bull.*, 30 2007: 2334-2339.
3. Dipak K Dash, Siva S Nayak, Soma Samanta, Tirtha Ghosh, Tarun Jha, Bhim C Maiti, Tapan K Maiti, Antitumor Activity and antioxidant Role of *Ichnocarpus frutescens* against Ehrlich Ascites Carcinoma in Swiss Albino Mice. *Natural Prod. Sciences*, 13 2007: 54-60
4. Samanta S, Debnath B, Tarafdar PK, De AU, Jha T. Search for Potential Anticancer Agents: Evaluation of Anticancer Activity of Solvent Evaporated Residue of Mother Tinctures of Some Homeopathic Medicines, *Hom. Herit.* 2008, **In Press**.

5. Vishnoi SP, Ghosh AK, Debnath B, Samanta S, Gayen S, Jha T, Antibacterial activity of *Abies webbiana*, *Fitoterapia*, 78 2007:153-155
6. Samanta S, Debnath B, Tarafdar PK, De AU, Jha T. Search for Potential Anticancer Agents: Evaluation of Anticancer Activity of Carcinosis, *Hom. Herit.* 2008, **In Press**
7. Samanta S, Sk. M.A, Panda P, Jha T. Pharmacophore Mapping of Tricyclic Isoxazoles for Their Affinity Towards Alpha-2Adrenoreceptors Internet Electron. *J. Mol. Des.*, 5 2006: 503-514.
8. Saha M, Ghosh D Jr, Ghosh D, Garai D, Jaisankar P, Sarkar KK, Dutta PK, Das S, Jha T, Mukherjee J. Studies on the production and purification of an antimicrobial compound and taxonomy of the producer isolated from the marine environment of the Sundarbans, *Appl. Microbiol. Biotechnol.*, 66 2005:497-505.
9. Gayen S, Debnath B, Samanta S, Ghosh B, Basu A, Jha T. 1,5-N,N'-Disubstituted-2-(Substituted Benzenesulphonyl)-Glutamamide Analogues as Anticancer Agents. Part 3. Synthesis, Biological Screening and QSAR Study, Internet Electron. *J. Mol. Des.*, 4 2005:556-578 www.biochempress.com
10. Debnath B, Samanta S, Gayen S, Basu A, Ghosh B, Jha T. QSAR Study on 5-N-Substituted-2-(Substituted Benzenesulphonyl) Glutamines as Antitumor Agents through Synthesis and Biological Evaluation: Part III, Internet Electron. *J. Mol. Des.*, 4 2005:393-412, www.biochempress.com
11. Debnath B, Tarafdar PK, De AU, Jha T. Search for potential anticancer agents: evaluation of anticancer activity of homeopathic Carcinosis, apis and thuja, *Hom. Herit.* 29 2004: 42-45.
12. Debnath B, Tarafdar PK, Jha T, De AU. Search for potential anticancer agents: characterization of some anticancer homeopathic medicines, *Hom. Herit.* 29 2004: 23-25.
13. Samanta S, Srikanth K, Banerjee S, Debnath B, Gayen S, Jha T. 5-N-Substituted-2-(Substituted Benzenesulphonyl) Glutamines as Antitumor Agents II: Synthesis, Biological Activity and QSAR Study, *Bioorg. Med. Chem.*, 12 2004:1413-1423.
14. Nayak SS, Ghosh AK, Debnath B, Vishnoi SP, Jha T. Synergistic effect of methanol extract of *Abies webbiana* leaves on sleeping time induced by standard sedatives in mice and anti-inflammatory activity of extracts in rats, *J. Ethnopharmacol.*, 93 2004: 397-402.
15. Nayak, S.S., Ghosh, A.K., Srikanth, K., Debnath, B. and Jha, T. Antitussive activity of *Abies webbiana* lindl leaf extract against sulphur dioxide induced cough reflex in mice, *Phytother. Res.*, 17 2003:930-932.
16. Debnath B, Srikanth K, Banarjee S, Jha T. 1,5-N, N'-Distubuted-2-(substituted benzenesulphonyl) glutamamides as antitumor agents. Part 2. synthesis, biological activity and QSAR study, Internet Electron, *J. Mol. Des.*, 1 2002:488-502, <http://www.biochempress.com>.
17. Srikanth, K., Debnath. B, Jha. T. Synthesis, biological evaluation and QSAR study on antitumor activity of 1,5-N, N'-distubuted-2-(substituted benzenesulphonyl) glutamamides, *Bioorg. Med. Chem.*, 10 2002:1841-1854.
18. Srikanth K, Kumar CA, Ghosh B, Jha T. Synthesis, screening and quantitative structure-activity relationship (QSAR) study on some glutamine analogues for possible anticancer activity, *Bioorg. Med. Chem.*, 10 2002:2119-2131.
19. Srikanth K, Debnath B, Nayak SS, Jha T. Enhanced regression of tumors in mice with combined chemotherapy and immunotherapy, *Ind. J. Pharmacol.*, 34 2002:172-177.
20. Ghosh AK, Srikanth K, Jha T. Inhibitory effects of *Abies webbiana* on tumor cells in mice, *Ind. J. Natl. Prod.*, 17 2001:17-19.
21. Jha T, Tarafdar PK and De AU. Search for potential anticancer agents: part 15 – effect of potentized and dynamized carcinosis on Ehrlich ascites carcinoma cell line in Swiss albino mice, *Homeo. Upd.* Winter 1998: 307-311.
22. Homeopathic Pharmacopoeia of India, New Delhi, Government of India, Ministry of Health and Welfare, 1990, Vol. VI., p. 127, 165, 173, 195.